Bryce P. Portier, Ph.D.

2006 University of Texas Medical Branch, Galveston, TX 
Molecular Biology, Cell Biology
"Bryce Portier"
Mean distance: 35622


Sign in to add mentor
Giulio Taglialatela grad student 2006 UTMB
 (Characterization of a novel pro-apoptotic role for nuclear associated Bcl-2.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Cagle PT, Raparia K, Portier BP. (2016) Emerging Biomarkers in Personalized Therapy of Lung Cancer. Advances in Experimental Medicine and Biology. 890: 25-36
Liu C, Pepper K, Hendrickson H, et al. (2015) Clinical Validation of a Novel Commercial Reverse Transcription-Quantitative Polymerase Chain Reaction Screening Assay for Detection of ALK Translocations and Amplifications in Non-Small Cell Lung Carcinomas. Archives of Pathology & Laboratory Medicine
Crumley SM, Pepper KL, Phan AT, et al. (2015) Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas. Archives of Pathology & Laboratory Medicine
Driver BR, Portier BP, Mody DR, et al. (2015) Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria. Archives of Pathology & Laboratory Medicine
Cagle PT, Olsen RJ, Portier BP, et al. (2015) A new ever-evolving paradigm. Archives of Pathology & Laboratory Medicine. 139: 446-7
Minca EC, Tubbs RR, Portier BP, et al. (2014) Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication. Cancer Genetics. 207: 306-15
Fiskus W, Sharma S, Qi J, et al. (2014) BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Molecular Cancer Therapeutics. 13: 2315-27
Fiskus W, Sharma S, Shah B, et al. (2014) Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 28: 2155-64
Portier BP, Kanagal-Shamanna R, Luthra R, et al. (2014) Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. American Journal of Clinical Pathology. 141: 559-72
Fiskus W, Sharma S, Qi J, et al. (2014) Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Molecular Cancer Therapeutics. 13: 1142-54
See more...